Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate SHR-1210 in Subjects With Advanced HCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically confirmed HCC in advanced stage; not suitable to surgery or local regional treatment; with at least one measurable lesion per RECIST 1.1~2. Failed or intolerable to at least one prior systemic treatment for advanced HCC~3. ECOG Performance Status of 0 or1~4. Child-Pugh Class A or B with 7 points~5. Life Expectancy of at least 12 weeks~6. HBV DNA\<500 IU/ml~7. Adequate organ function~8. Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug~Exclusion Criteria:~1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC~2. Known liver transplant or plan to transplant~3. GI hemorrhage with 6 months~4. History or current brain metastases~5. Active known, or suspected autoimmune disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SHR-1210 Q2W (Type: EXPERIMENTAL): Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
- SHR-1210 Q3W (Type: EXPERIMENTAL): Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).